Skip to content
OpenCapital
Get started

Exagen Inc. XGN Debt Issuance Cost Amortization

Debt Issuance Cost Amortization at other companies

Revvity logo
RevvityRVTY
$1.14M+3.4%

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%—

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s debt issuance cost amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s debt issuance cost amortization?
Exagen Inc. (XGN) reported debt issuance cost amortization of $133K in Q1 2026.
How has Exagen Inc.'s debt issuance cost amortization changed year-over-year?
Exagen Inc.'s debt issuance cost amortization increased by 216.7% year-over-year, from $42K to $133K.
What is the long-term trend for Exagen Inc.'s debt issuance cost amortization?
Over 4 years (2021 to 2025), Exagen Inc.'s debt issuance cost amortization has grown at a 7.9% compound annual growth rate (CAGR), from $279K to $378K.
What does debt issuance cost amortization mean?
Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).